On the basis of the involvement of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) in inflammation and vascular changes in COVID-19, we hypothesized that Dobesilate, a demonstrated anti-FGF and anti-VEGF drug might be beneficial for treating COVID-19 patients. We conducted a study and recruited 13 patients with long-COVID syndrome from one center. Dobesilate (Doxium® 1g, twice a day for 15 days) shows clinical efficacy by improving symptoms in these patients.
Key words: SARS-CoV-2, COVID-19, Long-COVID, Dobesilate
|
